122 related articles for article (PubMed ID: 16455079)
1. MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF).
Chebrolu H; Slevin JT; Gash DA; Gerhardt GA; Young B; Given CA; Smith CD
Exp Neurol; 2006 Apr; 198(2):450-6. PubMed ID: 16455079
[TBL] [Abstract][Full Text] [Related]
2. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.
Gill SS; Patel NK; Hotton GR; O'Sullivan K; McCarter R; Bunnage M; Brooks DJ; Svendsen CN; Heywood P
Nat Med; 2003 May; 9(5):589-95. PubMed ID: 12669033
[TBL] [Abstract][Full Text] [Related]
3. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
Lindvall O; Wahlberg LU
Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
[TBL] [Abstract][Full Text] [Related]
4. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
[TBL] [Abstract][Full Text] [Related]
5. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
Neurosurg Focus; 2006 May; 20(5):E1. PubMed ID: 16711657
[TBL] [Abstract][Full Text] [Related]
6. Crossroads in GDNF therapy for Parkinson's disease.
Sherer TB; Fiske BK; Svendsen CN; Lang AE; Langston JW
Mov Disord; 2006 Feb; 21(2):136-41. PubMed ID: 16470786
[TBL] [Abstract][Full Text] [Related]
7. GDNF therapy for Parkinson's disease.
Hong M; Mukhida K; Mendez I
Expert Rev Neurother; 2008 Jul; 8(7):1125-39. PubMed ID: 18590482
[TBL] [Abstract][Full Text] [Related]
8. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
Andereggen L; Meyer M; Guzman R; Ducray AD; Widmer HR
Brain Res; 2009 Jun; 1276():39-49. PubMed ID: 19389387
[TBL] [Abstract][Full Text] [Related]
9. Motor-related circuit dysfunction in MSA-P: Usefulness of combined whole-brain imaging analysis.
Tir M; Delmaire C; le Thuc V; Duhamel A; Destée A; Pruvo JP; Defebvre L
Mov Disord; 2009 Apr; 24(6):863-70. PubMed ID: 19194988
[TBL] [Abstract][Full Text] [Related]
10. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.
Patel NK; Bunnage M; Plaha P; Svendsen CN; Heywood P; Gill SS
Ann Neurol; 2005 Feb; 57(2):298-302. PubMed ID: 15668979
[TBL] [Abstract][Full Text] [Related]
11. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712
[TBL] [Abstract][Full Text] [Related]
12. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
[TBL] [Abstract][Full Text] [Related]
13. GDNF in Parkinson's disease: the perils of post-hoc power.
Matcham J; McDermott MP; Lang AE
J Neurosci Methods; 2007 Jul; 163(2):193-6. PubMed ID: 17540454
[TBL] [Abstract][Full Text] [Related]
14. Glial cell line-derived neurotrophic factor added to a sciatic nerve fragment grafted in a spinal cord gap ameliorates motor impairments in rats and increases local axonal growth.
Guzen FP; de Almeida Leme RJ; de Andrade MS; de Luca BA; Chadi G
Restor Neurol Neurosci; 2009; 27(1):1-16. PubMed ID: 19164849
[TBL] [Abstract][Full Text] [Related]
15. Changes of functional connectivity of the motor network in the resting state in Parkinson's disease.
Wu T; Wang L; Chen Y; Zhao C; Li K; Chan P
Neurosci Lett; 2009 Aug; 460(1):6-10. PubMed ID: 19463891
[TBL] [Abstract][Full Text] [Related]
16. Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI.
Blain CR; Barker GJ; Jarosz JM; Coyle NA; Landau S; Brown RG; Chaudhuri KR; Simmons A; Jones DK; Williams SC; Leigh PN
Neurology; 2006 Dec; 67(12):2199-205. PubMed ID: 17190944
[TBL] [Abstract][Full Text] [Related]
17. Intracerebral transplantation of genetically engineered cells for Parkinson's disease: toward clinical application.
Yasuhara T; Date I
Cell Transplant; 2007; 16(2):125-32. PubMed ID: 17474294
[TBL] [Abstract][Full Text] [Related]
18. [Growth factors as neuroprotective treatment in Parkinson disease?].
Torp R; Singh PB; Sørensen DR; Dietrichs E; Hirschberg H
Tidsskr Nor Laegeforen; 2006 Mar; 126(7):899-901. PubMed ID: 16554879
[TBL] [Abstract][Full Text] [Related]
19. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
[TBL] [Abstract][Full Text] [Related]
20. GDNF in Parkinson disease: an object lesson in the tyranny of type II.
Hutchinson M; Gurney S; Newson R
J Neurosci Methods; 2007 Jul; 163(2):190-2. PubMed ID: 16876872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
